Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lead Discovery Center GmbH is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. Such a narrow distribution reflects a singular point of focus for the company's current patent prosecution efforts. This concentration suggests that the pending application likely relates to a core pharmaceutical or biotechnological innovation that fits within a specific technical classification at the patent office.
LEESER, ERICH A serves as the busiest examiner for the portfolio, with 1 pending office action under review. Since the total number of pending office actions is 1, this examiner is responsible for all current activity. The alignment of 1 distinct examiner and 1 distinct art unit indicates that the prosecution is centralized within a specific niche. For the company, this means that the outcome of its current active prosecution depends entirely on the evaluation of this single examiner within their respective art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEESER, ERICH A | 1 | 81.9% | +13.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577397 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | LEESER, ERICH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577397 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | LEESER, ERICH A | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577397 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | LEESER, ERICH A | 1622 | §102 | Non-Final OA | — | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLead Discovery Center GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erich A Leeser has the most, with 1 of Lead Discovery Center GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
